Breaking News Instant updates and real-time market news.

EVER

EverQuote

$21.84

0.15 (0.69%)

, FPAY

FlexShopper

$1.68

0.195 (13.13%)

19:17
11/04/19
11/04
19:17
11/04/19
19:17

Fly Intel: After Hours Movers

UP AFTER EARNINGS: EverQuote (EVER) up 25.2%... FlexShopper (FPAY) up 13.6%... Chegg (CHGG) up 12.3%... Everbridge (EVBG) up 11.4%... RingCentral (RNG) up 10.2%... Iovance Biotherapeutics (IOVA) up 7.5%... ChemoCentryx (CCXI) up 5.8%... Jack Henry (JKHY) up 4.8%... Gaia (GAIA) up 3.5%... Tenet Healthcare (THX) up 2.0%... Hartford Financial (HIG) up 1.7%... Potbelly (PBPB) up 1.4%. ALSO HIGHER: Shenandoah Telecom (SHEN) up 11.4% after entering S&P 600 index... WWE (WWE) up 5.3% after expanding live event partnership in Saudi Arabia. DOWN AFTER EARNINGS: Myriad Genetics (MYGN) down 35.9%... Synchronoss (SNCR) down 15.9%... Shake Shack (SHAK) down 15.5%... Tandem Diabetes (TNDM) down 11.3%... McDermott International (MDR) down 10.4%... Diodes (DIOD) down 9.4%... Aaron's (AAN) down 8.0%... GroupOn (GRPN) down 6.7%... Mosaic (MOS) down 5.8%... Uber (UBER) down 5.1%... Maxar Technologies (MAXR) down 5.1%...Impinj (PI) down 4.3%... Endo International (ENDP) down 4.3%... Park-Ohio (PKOH) down 4.0%... Gladstone Investment (GAIN) down 3.9%... Capitala Finance (CPTA) down 3.8%... Helios Technologies (HLIO) down 2.3%... Marriott (MAR) down 2.2%... Prudential (PRU) down 1.8%... Hertz (HTZ) down 1.5%. ALSO LOWER: Yeti (YETI) down 4.6% after equity offering... Healthpeak Properties (HCP) down 1.8% after equity offering. Movers as of 18:45ET.

EVER

EverQuote

$21.84

0.15 (0.69%)

FPAY

FlexShopper

$1.68

0.195 (13.13%)

CHGG

Chegg

$29.30

-1.445 (-4.70%)

EVBG

Everbridge

$67.42

-3.52 (-4.96%)

RNG

RingCentral

$157.56

-4.38 (-2.70%)

IOVA

Iovance Biotherapeutics

$20.46

-1.5 (-6.83%)

CCXI

ChemoCentryx

$9.34

0.29 (3.20%)

JKHY

Jack Henry

$142.70

1.01 (0.71%)

GAIA

Gaia

$7.38

0.19 (2.64%)

THX

Houston Exploration

$0.00

(0.00%)

HIG

Hartford Financial

$57.52

-0.02 (-0.03%)

PBPB

Potbelly

$4.92

0.38 (8.37%)

SHEN

Shenandoah

$32.95

0.71 (2.20%)

WWE

WWE

$53.15

-2.805 (-5.01%)

MYGN

Myriad Genetics

$35.07

1.27 (3.76%)

SNCR

Synchronoss

$6.04

-0.09 (-1.47%)

SHAK

Shake Shack

$84.15

1.395 (1.69%)

TNDM

TNDM

MDR

McDermott

$1.72

0.06 (3.61%)

DIOD

Diodes

$48.95

0.8 (1.66%)

AAN

Aaron's

$74.00

0.005 (0.01%)

GRPN

Groupon

$3.01

0.14 (4.88%)

MOS

Mosaic

$21.36

0.72 (3.49%)

UBER

Uber

$31.09

-0.23 (-0.73%)

MAXR

Maxar Technologies

$9.94

0.985 (11.00%)

PI

Impinj

$33.45

-1.09 (-3.16%)

ENDP

Endo

$4.86

0.05 (1.04%)

PKOH

Park-Ohio

$32.54

0.69 (2.17%)

GAIN

Gladstone Investment

$12.95

0.02 (0.15%)

CPTA

Capitala Finance

$8.27

0.025 (0.30%)

HLIO

Helios Technologies

$42.18

0.69 (1.66%)

MAR

Marriott

$130.19

2.04 (1.59%)

PRU

Prudential

$94.63

1.66 (1.79%)

HTZ

Hertz

$14.13

0.4 (2.91%)

  • 04

    Nov

  • 04

    Nov

  • 04

    Nov

  • 04

    Nov

  • 04

    Nov

  • 04

    Nov

  • 04

    Nov

  • 04

    Nov

  • 04

    Nov

  • 04

    Nov

  • 04

    Nov

  • 04

    Nov

  • 04

    Nov

  • 04

    Nov

  • 04

    Nov

  • 04

    Nov

  • 04

    Nov

  • 05

    Nov

  • 05

    Nov

  • 05

    Nov

  • 05

    Nov

  • 05

    Nov

  • 05

    Nov

  • 05

    Nov

  • 05

    Nov

  • 05

    Nov

  • 05

    Nov

  • 05

    Nov

  • 05

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 08

    Nov

  • 09

    Nov

  • 10

    Nov

  • 11

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 14

    Nov

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 21

    Nov

  • 25

    Nov

  • 26

    Nov

  • 04

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

EVER EverQuote
$21.84

0.15 (0.69%)

08/06/19
08/06/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Northrop Grumman (NOC) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Rajeev Lalwani citing his view that an opportunity for continued outperformance exists in Defense stocks. 2. Bancolombia (CIB) upgraded to Overweight from Neutral at JPMorgan and to Neutral from Underperform at Credit Suisse. 3. Ford (F) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Adam Jonas saying Ford's partnerships and "more focused" model lineup should keep its profitability "largely stable" through 2022. 4. Aimco (AIV) upgraded to Buy from Neutral at Mizuho with analyst Haendel St. Juste saying the company trades at a "two-turn multiple discount" to peers based on estimates 2020 funds from operations as well as a 10% discount to consensus net asset value versus peers' 2% premium. 5. EverQuote (EVER) upgraded to Outperform from Market Perform at Raymond James with analyst Aaron Kessler citing the company's "strong" Q2 results and outlook. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/20/19
NEED
08/20/19
NO CHANGE
Target $27
NEED
Buy
EverQuote price target raised to $27 from $20 at Needham
Needham analyst Mayank Tandon raised his price target on EverQuote to $27 and kept his Buy rating after meeting with its CFO John Wagner for the inaugural FinTech 1X1Conference. The analyst says the discussions boosted his confidence that the company can sustain its "robust" operating momentum given the "strong demand" from insurance carriers and agents, along with its improvements in execution. Tandon adds that EverQuote has demonstrated its ability to attract customers to its platform thanks to its "user-friendly experience and sizable cost savings."
09/17/19
BOFA
09/17/19
DOWNGRADE
Target $16.5
BOFA
Underperform
EverQuote downgraded to Underperform from Buy at BofA/Merrill
BofA/Merrill analyst Nat Schindler double downgraded EverQuote to Underperform from Buy, but raised his price target to $16.50 from $13.75. The analyst remains positive on EverQuote's underlying business and long-term growth potential, but is concerned with valuation given recent outperformance as shares are up 500% year-to-date.
09/17/19
09/17/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Home Depot (HD) downgraded to Neutral from Buy at Guggenheim with analyst Steven Forbes saying he finds it hard to see a path to EBIT margin expansion in 2020 given the company's planned investment spending. 2. The Medicines Co. (MDCO) downgraded to Neutral from Buy at Citi with analyst Joel Beatty saying the shares are up ~40% since the initial topline Phase 3 results were announced in late August. 3. Actuant (ATU) downgraded to Sector Weight from Overweight at KeyBanc and to Hold from Buy at Gabelli. 4. EverQuote (EVER) downgraded to Underperform from Buy at BofA/Merrill with analyst Nat Schindler saying he remains positive on EverQuote's underlying business and long-term growth potential, but is concerned with valuation given recent outperformance as shares are up 500% year-to-date. 5. Atlas Air (AAWW) downgraded to Neutral from Positive at Susquehanna. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
FPAY FlexShopper
$1.68

0.195 (13.13%)

04/09/19
ASCN
04/09/19
INITIATION
Target $3
ASCN
Buy
FlexShopper initiated with a Buy at Ascendiant
Ascendiant initiated FlexShopper with a Buy and $3 price target.
06/24/19
SPHN
06/24/19
UPGRADE
Target $27
SPHN
Equal Weight
Rent-A-Center upgraded to Equal Weight from Underweight at Stephens
Stephens analyst Vincent Caintic upgraded Rent-A-Center (RCII) to Equal Weight from Underweight citing what he sees as "massive potential" for third-party retailer Rent-To-Own, telling investors that he wouldn't want to be short any Rent-To-Own stock he covers as a result. However, he thinks Rent-A-Center's "Acceptance Now" offering trails those of publicly traded peers Aaron's (AAN), Curo Group (CURO) and FlexShopper (FPAY), Caintic tells investors. He keeps his Rent-A-Center EPS expectations slightly below guidance, as he is still cautious on execution, but raised his price target on the stock to $27 from $20 to account for a higher multiple.
10/10/19
MAXM
10/10/19
INITIATION
Target $3
MAXM
Buy
FlexShopper initiated with a Buy rating at Maxim
Maxim analyst Michael Diana initiated coverage of FlexShopper with a Buy rating and $3.00 price target.
10/10/19
MAXM
10/10/19
INITIATION
Target $3
MAXM
Buy
FlexShopper initiated with a Buy, $3 price target at Maxim
Maxim analyst Michael Diana initiated coverage of FlexShopper (FPAY) with a Buy rating and $3 price target, saying valuation is at a discount to rent-to-own giants Aaron's (AAN) and Rent-A-Center (RCII), but thinks FlexShopper's business model is "superior."
CHGG Chegg
$29.30

-1.445 (-4.70%)

08/13/19
WBLR
08/13/19
INITIATION
WBLR
William Blair starts Chegg, K12 with Outperform ratings
William Blair analyst Stephen Sheldon yesterday afternoon initiated coverage of Chegg (CHGG) and K12 (LRN) with Outperform ratings, and of 2U (TWOU) with a Market Perform rating. The analyst also assumed coverage of Instructure (INST) with a Market Perform rating following an analyst departure earlier this year. The amount spent annually on traditional education is large and growing, estimated to reach close to $1.5 trillion in the United States, Sheldon wrote in a research note. There are "numerous pain points" in the education industry, and solutions from education technology providers are helping alleviate some of these "highly complex" issues, adds the analyst. He believes that Chegg should be able to deliver at least 20% revenue growth over the next three years and that K12 can deliver mid-single-digit revenue growth over time. For 2U, Sheldon believes tge shares will be range-bound until the company provides clarity on its long-term model and "rebuilds trust."
09/09/19
JEFF
09/09/19
UPGRADE
Target $44
JEFF
Buy
Chegg upgraded to Buy from Hold at Jefferies
Jefferies analyst Brent Thill upgraded Chegg to Buy from Hold while lowering his price target for the shares to $44 from $46.
09/09/19
JEFF
09/09/19
UPGRADE
Target $44
JEFF
Buy
Chegg 'skating to where the puck is headed,' Jefferies says in upgrade
Jefferies analyst Brent Thill upgraded Chegg to Buy from Hold while lowering his price target for the shares to $44 from $46. The recent pullback in the shares represents a buying opportunity, Thill tells investors in a research note. The company, by creating a full service learning platform and expanding its addressable market with product updates and acquisitions, is "skating to where the puck is headed," says the analyst. He sees Chegg as a "consistent" 20%-plus growth story with expanding margins and a market leading position. Thill views the company as "one of the best fundamental stories in Smid cap Internet."
10/04/19
BMOC
10/04/19
NO CHANGE
Target $35
BMOC
Outperform
Chegg price target lowered to $35 from $49 at BMO Capital
BMO Capital analyst Jeffrey Silber lowered his price target on Chegg to $35, updating his model to reflect the company's recently announced $80M acquisition of Thinkful and the multiple contraction following the disclosure of the deal. The analyst notes that the company has acknowledged the initial adverse EBITDA impact from the acquisition but also keeps his Outperform rating on the stock, stating that Chegg "continues to invest in content and services" to attract more subscribers and increase its total addressable market.
EVBG Everbridge
$67.42

-3.52 (-4.96%)

06/21/19
ADAM
06/21/19
NO CHANGE
Target $105
ADAM
Buy
Everbridge price target raised to $105 from $85 at Canaccord
Canaccord analyst Richard Davis raised his price target on Everbridge to $105 from $85 following its analyst day meeting. The analyst noted the company has little competition and there are a number of significant growth prospects including the international expansion opportunity, the continued introduction of new products to the CEM suite, and the continuation of steady M&A to drive organic growth. Davis reiterated his Buy rating on Everbridge shares.
06/21/19
NORL
06/21/19
NO CHANGE
Target $105
NORL
Outperform
Everbridge price target raised to $105 from $83 at Northland
Northland analyst Michael Latimore raised his price target on Everbridge shares to $105 from $83 after the company held its second analyst day. The event detailed multiple growth opportunities and the company's growing competitive differentiation, according to Latimore, who keeps an Outperform rating on the stock.
08/06/19
RAJA
08/06/19
NO CHANGE
Target $100
RAJA
Outperform
Everbridge price target raised to $100 from $82 at Raymond James
Raymond James analyst Brian Peterson raised his price target for Everbridge to $100 from $82 and reiterated an Outperform rating following better than expected second quarter results. In a research note to investors, Peterson says that while he agrees that quarterly billings variances can cause overreactions, he thinks that the nearly 20 point deceleration in TTM billings is more than investors expected, but says he heard nothing to change his positive fundamental stance on shares.
09/09/19
BARD
09/09/19
NO CHANGE
Target $100
BARD
Outperform
Everbridge weakness a buying opportunity, says Baird
Baird analyst William Power said the weakness in Everbridge is a buying opportunity. He noted the shares dropped last week on a combination of broader high multiple SaaS weakness and a possible delayed reaction to a management change announced on Wednesday. He believes the new Chief Revenue Officer should benefit the company both medium and long-term nd he remains positive on the company's multiple growth opportunities. Power reiterated his Outperform rating and $100 price target on Everbridge shares.
RNG RingCentral
$157.56

-4.38 (-2.70%)

10/07/19
JPMS
10/07/19
UPGRADE
Target $225
JPMS
Overweight
JPMorgan upgrades RingCentral to Overweight on Avaya partnership
JPMorgan analyst Sterling Auty upgraded RingCentral (RNG) to Overweight from Neutral with a price target of $225, up from $143. The Avaya (AVYA) transaction announced last week opens up an opportunity to "dramatically accelerate" RingCentral's shift to cloud-based unified communications as a service solutions, Auty tells investors in a research note. The analyst believes the deal structure provides attractive economics to both sides, as well as protections for RingCentral. Penetrating as little as 3%-5% of Avaya's 100M-plus customer base is worth an incremental $82 per share, Auty estimates.
10/07/19
NEED
10/07/19
NO CHANGE
Target $65
NEED
Buy
Five9 may be 'quiet winner' of Avaya-Ring Central deal, says Needham
Needham analyst Scott Berg notes that Five9 (FIVN) may be the "quiet winner" from the Cloud solution partnership announced last week between Avaya (AVYA) and Ring Central (RNG), keeping his Buy rating and $65 price target on on the stock. The analyst notes Avaya has about a third of the cloud contact center, or CC, market, and contends that any of its customers' move to an "ACO solution" customer's CC infrastructure. Berg adds that while the pace of the potential customer conversion to ACO is unknown, the migration will pull forward the CC infrastructure decisions, which should be favorable for Five9 because of its "industry-leading CC platform and win rates."
10/22/19
RSBL
10/22/19
NO CHANGE
RSBL
Zoom Video relationship with RingCentral starting to 'fracture,' says Rosenblatt
Rosenblatt analyst Ryan Koontz said his check indicate that RingCentral's (RNG) strategic relationship with Zoom Video (ZM) "may be beginning to fracture earlier than anticipated" as the former begins investing heavily in its new strategic alliance with Avaya (AVYA). He also believes that his suspicions that RingCentral is developing its own video meeting product could be announced shortly and he thinks RingCentral may bring to market an initially inferior video product in an effort to halt the proliferation of Zoom video in its customer base if the current situation continues to escalate. Koontz keeps a Neutral rating on Zoom Video shares.
10/28/19
JEFF
10/28/19
NO CHANGE
Target $210
JEFF
Buy
Jefferies boosts RingCentral target to $210, adds to Franchise Picks List
Jefferies analyst Samad Samana raised his price target for RingCentral (RNG) to $210 from $152 and added the shares to his firm's Franchise Picks List. The stock closed Friday up $5.65 to $160.36. Despite the 26% rally since the Avaya (AVYA) partnership announcement, the company's potential remains underappreciated, Samana tells investors in a research note. Through a combination of organic growth and contribution from Avaya, RingCentral's path to greater than $2B in revenue is "much clearer," says the analyst. He expects the company's subscription revenue to reach $2.4B in 2023, or more than triple his 2019 estimate. Samana keeps a Buy rating on RingCentral shares.
IOVA Iovance Biotherapeutics
$20.46

-1.5 (-6.83%)

07/02/19
PIPR
07/02/19
NO CHANGE
Target $30
PIPR
Overweight
Iovance submission on track for second half of 2020, says Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro says guidance from the FDA, as announced this morning by the company, puts Iovance Biotherapeutics on track for a Biologics License Application in cervical cancer in the second half of 2020. This is a positive outcome and largely in-line with where consensus has moved following the ASCO presentation, Catanzaro tells investors in a research note. He maintains an Overweight rating on Iovance Biotherapeutics with a $30 price target.
07/02/19
HCWC
07/02/19
NO CHANGE
Target $32
HCWC
Buy
H.C. Wainwright reiterates Buy, $32 price target on Iovance
H.C. Wainwright analyst Joseph Pantginis reiterates a Buy rating on Iovance Biotherapeutics with a $32 price target after the company disclosed updates regarding the regulatory path for LN-145 in cervical cancer. With the possibility for innovaTIL-04 study to be registrational, the company is "reasonably" planning a path for a Biologics License Application submission in the second half of 2020, Pantginis tells investors in a research note. The analyst believes LN-145 "deserves the attention it is receiving." While the primary focus remains on Iovance's initial path to market with lifileucel in melanoma, LN-145 is a "potential rapid follower to commercialization," says Pantginis.
08/26/19
JEFF
08/26/19
NO CHANGE
Target $33
JEFF
Buy
Iovance pullback brings buying opportunity, says Jefferies
Jefferies analyst Biren Amin views the recent pullback in shares of Iovance Biotherapeutics as a buying opportunity into the end of 2019. After meeting with management, the analyst believes the melanoma and cervical pivotal cohorts appear to be enrolling patients with Iovance on track toward finishing patient enrollment in the melanoma study in Q1 of 2020. He thinks there is some likelihood of data at SITC in November and keeps a Buy rating on the shares with a $33 price target.
09/30/19
STFL
09/30/19
INITIATION
Target $27
STFL
Buy
Iovance Biotherapeutics initiated with a Buy at Stifel
Stifel analyst Benjamin Burnett started Iovance Biotherapeutics with a Buy rating and $27 price target. The analyst says his physician checks corroborate the view that the company's lifileucel and LN-145 data are "very good" and supportive of being the best therapeutic option in their respective advanced settings. He believes the market opportunity for an autologous tumor-infiltrating lymphocyte product in the advanced melanoma/cervical cancer setting can reach $2B-plus sales at peak.
CCXI ChemoCentryx
$9.34

0.29 (3.20%)

06/06/19
RAJA
06/06/19
NO CHANGE
Target $17
RAJA
Strong Buy
ChemoCentryx price target lowered to $17 from $24 at Raymond James
Raymond James analyst Steven Seedhouse removed hidradenitis suppurativa from his model for ChemoCentryx (CCXI) after InflaRx (IFRX) reported that its Phase IIb trial for C5a antibody IFX-1 failed, leading him to lower his price target on the shares to $17 from $24. However, he keeps a Strong Buy rating on ChemoCentryx shares and said he would be a buyer amid the weakness, citing Phase 2 data for avacopan in AAV and a near-term Phase 3 data readout for AAV in Q4.
09/12/19
JPMS
09/12/19
UPGRADE
Target $14
JPMS
Overweight
ChemoCentryx upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Anupam Rama upgraded ChemoCentryx to Overweight from Neutral with a price target of $14, down from $16. The analyst sees a favorable risk/reward profile at current share levels.
09/12/19
JPMS
09/12/19
UPGRADE
Target $14
JPMS
Overweight
JPMorgan upgrades ChemoCentryx to Overweight ahead of Phase 3 readout
JPMorgan analyst Anupam Rama upgraded ChemoCentryx to Overweight from Neutral with a price target of $14, down from $16. Following a round of key opinion leader and physician discussions, the analyst believes the Phase 3 Advocate study of avacopan in associated vasculitis has a high probability of success. The share pressure dating back to the spring has created a favorable risk/reward scenario for shares of ChemoCentryx ahead of the Phase 3 results, Rama tells investors in a research note. The analyst expects the readout in the mid-to-late Q4 timeframe.
10/15/19
JPMS
10/15/19
NO CHANGE
JPMS
Overweight
ChemoCentryx can rally 110% on positive Advocate results, says JPMorgan
JPMorgan analyst Anupam Rama says shares ChemoCentryx can rally 90%-110% on positive Phase 3 Advocate trial results of avacopan in ANCA-associated vasculitis, expected in Q4. The analyst sees share downside of 45%-80% on negative results. Rama continues to believe that Advocate has a high probability of success and that the totality of data will be key for adoption. He keeps an Overweight rating on ChemoCentryx shares.
JKHY Jack Henry
$142.70

1.01 (0.71%)

05/24/19
SPHN
05/24/19
NO CHANGE
SPHN
Global Payments, TSYS tie-up would likely be highly accretive, says Stephens
Stephens analyst Brett Huff noted that Bloomberg reports that Global Payments (GPN) and TSYS (TSS) have held talks about a potential merger, joint venture and/or partnerships. While he has previously thought that Global Payments had the luxury of "waiting and seeing" if combining consumer funding account with a merchant POS experience, such as the Fiserv (FISV)-First Data (FDC) and FIS (FIS)-Worldpay (WP) deals will do, would yield enough strategic value, he suspects a sooner deal might be driven by the companies' desire to not just achieve larger scale but also achieve that scale with high-quality assets. Huff said he thinks any deal would likely be highly accretive given overlaps and both companies' track record for realizing cost synergies and he also sees limited antitrust concern. Huff also thinks a Global Payments-TSYS combination would increase the chances that assets such as ACI Worldwide (ACIW), Bottomline Technologies (EPAY), Jack Henry (JKHY), USA Technologies (USAT) and Q2 Holdings (QTWO) would likely be bought.
09/03/19
ATLE
09/03/19
INITIATION
Target $147
ATLE
Neutral
Jack Henry initiated with a Neutral at Atlantic Equities
Atlantic Equities started Jack Henry with a Neutral rating and $147 price target.
09/03/19
ATLE
09/03/19
INITIATION
Target $147
ATLE
Neutral
Jack Henry initiated with a Neutral at Atlantic Equities
Atlantic Equities analyst Kunaal Malde initiated coverage of Jack Henry & Associates with a Neutral rating and $147 price target. The company is a consistent share gainer in Bank Tech but this trend is well understood by investors, Malde tells investors in a research note. Jack Henry's valuation is much higher than peers relative to the company's earnings growth and its smaller bank customer base is under secular pressure, adds the analyst.
09/03/19
ATLE
09/03/19
INITIATION
Target $50
ATLE
Underweight
Atlantic Equities starts Square with Underweight rating, $55 price target
Atlantic Equities analyst Kunaal Malde initiated coverage of Square (SQ) with an Underweight rating and $55 price target. The shares closed Friday at $61.84. Square's core business is decelerating and the mix shift to consumer payments increases uncertainty, Malde tells investors in a research note. The company's core merchant acquiring yields are too high versus peers that are increasingly competing with combined hardware/software platforms, adds the analyst. Further, he points out that PayPal's (PYPL) Venmo is regaining ground on Square's Cash App. Malde this morning also initiated coverage of FIS (FIS) with an Overweight rating as well as Fiserv (FISV) and Jack Henry (JKHY) with Neutral ratings.
GAIA Gaia
$7.38

0.19 (2.64%)

03/01/19
RILY
03/01/19
NO CHANGE
Target $24
RILY
Buy
B. Riley adds Gaia, removes TiVo from Alpha Generator list
B. Riley FBR analyst Eric Wold added Gaia (GAIA) to his firm's Alpha Generator list while removing TiVo (TIVO). The analyst anticipates Gaia's board will take steps to accelerate profitability amid growing investor concerns around balance sheet preservation. He projects the company could reach profitability by around mid-2019 and still generate net subscriber growth of 30%-40% in 2019. The "profitability pivot" should a "meaningful near-term re-rating" for the shares, Wold tells investors in a research note. He keeps a Buy rating on Gaia with a $24 price target. The analyst maintains a Buy rating on TiVo with a $23 price target.
03/05/19
LSCM
03/05/19
NO CHANGE
Target $20
LSCM
Buy
Gaia price target lowered to $20 from $28 at Lake Street
Lake Street analyst Mark Argento lowered his price target for Gaia to $20 saying the company is taking a more prudent approach to subscriber acquisition by focusing on acquiring higher return on investment and quality subscribers using internally generated cash flow while preserving liquidity. The analyst believes the market for Gaia's content "remains sizable but it is prudent to manage customer acquisition capital given the current environment." He keeps a Buy rating on the shares.
06/17/19
RILY
06/17/19
NO CHANGE
Target $71
RILY
Buy
Brunswick added to Alpha Generator list, Gaia removed, at B. Riley FBR
B. Riley FBR analyst Eric Wold added Brunswick (BC) to his firm's Alpha Generator list while removing Gaia (GAIA). Macroeconomic trends are favorable Brunswick with the highest rainfall in 120-plus years impacting boat purchases, so far, this year, Wold tells investors in a research note. The analyst points out that his dealer and management discussions in recent weeks have become noticeably more positive. He keeps a Buy rating on Brunswick shares with a $71 price target. Gaia also remains Buy rated with a $22 price target.
08/06/19
LSCM
08/06/19
NO CHANGE
Target $15
LSCM
Buy
Gaia price target lowered to $15 from $20 at Lake Street
Lake Street analyst Mark Argento lowered his price target for Gaia to $15 from $20 saying the company reported a "mixed quarter" as the reduction of subscriber acquisitions started to benefit Q2's bottom line. The market for Gaia's content remains sizable and the stock has "overcorrected" for the need to decelerate growth, Argento tells investors in a research note. The analyst maintains a Buy rating on Gaia shares.
THX Houston Exploration
$0.00

(0.00%)

HIG Hartford Financial
$57.52

-0.02 (-0.03%)

08/05/19
RBCM
08/05/19
NO CHANGE
Target $68
RBCM
Outperform
Hartford Financial price target raised to $68 from $61 at RBC Capital
RBC Capital analyst Mark Dwelle raised his price target on Hartford Financial to $68 and kept his Outperform rating, saying the company posted "good core results" in Q2 with low 90s underlying combined ratios for both commercial and personal lines. The analyst also notes that the former is generating accelerating pricing trends, and the management commentary suggests the integration of Navigators and the company's growth plans are "proceeding well".
10/01/19
JPMS
10/01/19
NO CHANGE
JPMS
JPMorgan shifts Life Insurance view to negative from neutral
JPMorgan analyst Jimmy Bhullar shifted is view on the Life Insurance sector to negative from neutral ahead of the Q3 reporting season. His outlook for business fundamentals is "incrementally cautious" and he feels that consensus 2020 earnings estimates for most insurers are too high. In addition, stock prices do not seem to have reacted to the decline in interest rates, Bhullar tells investors in a research note. The analyst lowered his estimates for most companies, and his numbers for 2020 are now "considerably below" consensus on AIG (AIG), Hartford Financial (HIG), and Voya Financial (VOYA), but slightly above for Aflac (AFL) and Unum Group (UNM). For Q3, Bhullar thinks consensus estimates for Athene Holding (ATH) and Reinsurance Group (RGA) are" especially high," while numbers for Principal Financial (PFG) "seem conservative." Globe Life (GL) and Lincoln National (LNC) are the analyst's top picks and he remains negative on Brighthouse Financial (BHF).
10/16/19
EVER
10/16/19
UPGRADE
EVER
Outperform
Hartford Financial upgraded to Outperform from In Line at Evercore ISI
10/17/19
EVER
10/17/19
UPGRADE
EVER
Outperform
Hartford Financial upgraded to Outperform from In Line at Evercore ISI
Evercore ISI analyst David Motemaden took over coverage of Hartford Financial from Tom Gallagher and upgraded the stock to Outperform from In-Line.
PBPB Potbelly
$4.92

0.38 (8.37%)

05/08/19
MAXM
05/08/19
DOWNGRADE
MAXM
Hold
Potbelly downgraded to Hold from Buy at Maxim
Maxim analyst Stephen Anderson downgraded Potbelly to Hold from Buy following the company's earnings and revenue miss in Q1.
05/08/19
05/08/19
DOWNGRADE
Target $8

Hold
Potbelly downgraded to Hold at Maxim on 'disappointing' Q1 results
As previously reported, Maxim analyst Stephen Anderson downgraded Potbelly to Hold and lowered his price target to $8 from $11 following the company's "disappointing" Q1 results and a cut in its FY19 guidance. The analyst adds that Potbelly's 4.7% comp decline was "far worse" than expected, also lowering his FY19 EPS view to 2c from 25c after the quarter.
SHEN Shenandoah
$32.95

0.71 (2.20%)

08/07/19
RAJA
08/07/19
UPGRADE
RAJA
Outperform
Shenandoah upgraded to Outperform from Market Perform at Raymond James
WWE WWE
$53.15

-2.805 (-5.01%)

11/01/19
GUGG
11/01/19
NO CHANGE
Target $85
GUGG
WWE price target lowered to $85 from $100 at Guggenheim
Guggenheim analyst Curry Baker lowered his 2020 adjusted OIBDA estimate for WWE and cut his price target on the stock to $85 from $100 after the company announced accelerated investment to support content creation and lowered its full-year FY19 guidance. Baker expects an announcement for the India renewal by year end, but now assumes only a 2.2 times step-up in average annual value, down from his prior forecast for a step-up of 4 to 4.5 times. He also assumes a flat U.K. deal and a 1.5 times step-up for its other international deals. Baker maintains a Buy rating on WWE shares.
11/01/19
MKMP
11/01/19
NO CHANGE
Target $92
MKMP
Buy
WWE price target lowered to $92 from $110 at MKM Partners
MKM Partners analyst Eric Handler lowered his price target on WWE to $92 after its Q3 results and a cut in its FY19 OIBDA view to $180M-$190M from "at least" $200M. The analyst still keeps his Buy rating on the stock, stating that the issues weighing on the guidance are likely "short lived" while also maintaining his view of WWE as having the "best multi-year growth outlook" in his Media & Entertainment coverage universe.
11/01/19
MSCO
11/01/19
NO CHANGE
Target $80
MSCO
Overweight
WWE shares oversold following 'surprise' guidance cut, says Morgan Stanley
Morgan Stanley analyst Benjamin Swinburne thinks the optics of WWE choosing to increase its content spend in Q4, when it was already facing a full-year revenue shortfall, and its "surprise" guidance cut helped fuel a greater than 15% selloff in the shares, but he views the move as an overreaction and thiks the stock was "already undervalued." He contends that less has changed than the selloff implies and believes WWE is "still a growth business" with unique intellectual property. Swinburne lowered his price target on WWE shares to $80 from $85 but keeps an Overweight rating on the shares.
11/01/19
LOOP
11/01/19
NO CHANGE
Target $75
LOOP
Buy
WWE price target lowered to $75 from $100 at Loop Capital
Loop Capital analyst Alan Gould lowered his price target on WWE to $75 after its Q3 results and a cut in its FY19 OIBDA outlook. The analyst says the reduced guidance was due to increased spending and a delay in signing of its Mideast TV contract. Gould still keeps his Buy rating on WWE and believes that the company's move of "SmackDown" program to FOX in October gave a "strong boost" to its ratings, which should benefit the company's overall brand.
MYGN Myriad Genetics
$35.07

1.27 (3.76%)

09/24/19
PIPR
09/24/19
NO CHANGE
Target $40
PIPR
Neutral
Myriad competitor allowed to keep pharmacogenomic stoplight, says Piper Jaffray
Myriad Genetics competitor Genomind resumed including specific drug recommendations in physician reports following interaction with FDA, but only for physician clients as patient reports only include the genotype information, Piper Jaffray analyst William Quirk tells investors in a research note. While there remains considerable uncertainty in the pharmacogenomics landscape, the recent move by Genomind is a positive read through for Myriad's GeneSight, says the analyst. He points out that several industry groups are lobbying the FDA to reverse their recent action against pharmacogenomic Clinical Laboratory Improvement Amendments-certified labs. This suggests the GeneSight psychotropic test report could remain on market as is, contends Quirk. He keeps a Neutral rating on shares of Myriad Genetics.
09/25/19
LEHM
09/25/19
NO CHANGE
Target $22
LEHM
Underweight
Barclays, following 'regulatory breadcrumbs,' stays Underweight on Myriad
The most important debate for shares of Myriad Genetics remains potential regulatory action for GeneSight, Barclays analyst Jack Meehan tells investors in a research note. The analyst believes recent "regulatory breadcrumbs" confirm the risks inherent in his Underweight thesis on Myriad shares. The most recent important update was a letter submitted by the American Clinical Laboratory Association to the FDA on September 18 saying that the ACLA is "Deeply Concerned by FDA Actions on Pharmacogenetic Testing," says Meehan. If the lab industry were having positive FDA dialogue, there would have been no need to publish a formal four-page letter raising concerns about the regulatory review taking place, contends the analyst. He believes potential premarket approval application review of the test would raise further regulatory risk for GeneSight.
09/26/19
BOFA
09/26/19
DOWNGRADE
BOFA
Underperform
Myriad Genetics downgraded to Underperform from Neutral at BofA/Merrill
09/26/19
BOFA
09/26/19
UPGRADE
BOFA
Buy
Bruker, PerkinElmer, Personalis upgraded to Buy at BofA/Merrill
BofA/Merrill analyst Derik de Bruin upgraded Bruker (BRKR), PerkinElmer (PKI), and Personalis (PSNL) to Buy from Neutral as part of his broader research note into Life Sciences & Diagnostic Tools. The analyst notes that the recent market volatility has sent many of the names in the sector "sharply lower", making their valuations more attractive. de Bruin is also positive on Bruker's new product portfolio and margin expansion opportunity. As part of the research note, the analyst cuts Myriad Genetics (MYGN) to Underperform from Neutral and lowers his price target on the shares to $28 from $30 after a bounce in its stock price and given his concern with its mixed execution.
SNCR Synchronoss
$6.04

-0.09 (-1.47%)

06/18/19
ROTH
06/18/19
INITIATION
Target $13
ROTH
Buy
Synchronoss initiated with a Buy at Roth Capital
Roth Capital analyst Richard Baldry started coverage of Synchronoss with a Buy rating and $13 price target. The analyst believes Synchronoss' "unique set" of cloud-based offerings address important new strategic growth avenues for a broadening set of potential customers and expects its depressed valuation to rebound over the year ahead.
08/27/19
ADAM
08/27/19
INITIATION
Target $13
ADAM
Buy
Synchronoss initiated with a Buy at Canaccord
Canaccord analyst Michael Walkley initiated Synchronoss with a Buy and $13 price target.
08/27/19
ADAM
08/27/19
INITIATION
Target $13
ADAM
Buy
Synchronoss initiated with a Buy at Canaccord
As reported previously, Canaccord analyst T. Michael Walkley initiated Synchronoss with a Buy rating as the company has reemerged as a leading TMT software an services provider. The analyst said its current valuation is compelling based on conservative estimates as the market is giving little credit to the improving trends implemented by new management. Walkley has a $13 price target on Synchronoss shares.
09/09/19
ADAM
09/09/19
NO CHANGE
Target $13
ADAM
Buy
Synchronoss weakness a buying opportunity, says Canaccord
Canaccord analyst T. Michael Walkley said the weakness in Synchronoss (SNCR) shares following a short report by Value Investors Club, is a buying opportunity. The analyst said the report suggested Verizon's (VZ) cloud business could face material revenue declines, discusses the well known STI risks, and assumes the company has limited access to new capital to refinance it convertible preferred equity. In addition to explaining each of the points, the analyst said the report does not account for the new major carrier deal that should be announced soon which he believes will be a key driver for Cloud growth in 2020. Walkley reiterated his Buy rating and $13 price target on Synchronoss shares.
SHAK Shake Shack
$84.15

1.395 (1.69%)

09/30/19
DBAB
09/30/19
INITIATION
Target $90
DBAB
Hold
Shake Shack initiated with a Hold at Deutsche Bank
Deutsche Bank started Shake Shack with a Hold rating and $90 price target.
09/30/19
DBAB
09/30/19
INITIATION
Target $90
DBAB
Hold
Deutsche Bank starts Shake Shack at Hold, says wait for better entry point
Deutsche Bank analyst Brian Mullan initiated coverage of Shake Shack with a Hold rating and $90 price target. The stock closed Friday down $2.01 to $95.52. Shake Shack is a "truly differentiated brand" within the restaurant industry and has a "compelling" long-term growth opportunity, Mullan tells investors in a research note. However, with the shares up 115% year-to-date, the analyst thinks the market is pricing in a lot of the positive factors at this point in time. As such, he advocates patience and prefers to wait for a better entry point into Shake Shack shares.
09/30/19
09/30/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Shake Shack (SHAK) initiated with a Hold at Deutsche Bank. 2. Bellus Health (BLU) initiated with a Buy at Jefferies as well as Guggenheim, and an Outperform at Cowen. 3. Idex Corp. (IEX) initiated with a Neutral at Citi. 4. Global Ship Lease (GSL) initiated with a Buy at B. Riley FBR. 5. Murphy Oil (MUR) initiated with an Outperform at BMO Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/25/19
WEDB
10/25/19
NO CHANGE
Target $84
WEDB
Neutral
Wedbush favors Dine Brands, 'cautious' on Cheesecake Factory into Q3 earnings
Wedbush analyst Nick Setyan told investors in a research note that he favors Applebee's parent Dine Brands (DIN) and is "cautious" on Cheesecake Factory (CAKE) ahead of Q3 their earnings reports. The analyst raised his price target for Shake Shack (SHAK) to $84 from $75, but lowered his price targets for Dunkin' Brands (DNKN) to $90 from $92, for Cheesecake Factory to $40 from $43, for Starbucks (SBUX) to $86 from $95, for Texas Roadhouse (TXRH) to $52 from $60 and for Wingstop (WING) to $88 from $92.
TNDM TNDM

10/15/19
OPCO
10/15/19
NO CHANGE
OPCO
Outperform
DexCom should be bought after 'negative' Tandem headline, says Oppenheimer
Oppenheimer analyst Steven Lichtman said Tandem Diabetes' (TNDM) announcement that it is exploring integrated solutions with Abbott (ABT) is a potential long-term positive as integration with the latter's Libre system would expand the former's reach with patients. While a "negative headline" for DexCom (DXCM), he would be a buyer on weakness, arguing that it is still early in the process and DexCom "continues to march forward toward" G-7, with a limited launch of the CGM expected in late 2020. Lichtman has Outperform ratings on both Tandem and DexCom.
10/17/19
LSCM
10/17/19
NO CHANGE
Target $100
LSCM
Buy
Tandem Diabetes partnership offers 'substantial opportunity,' says Lake Street
Lake Street analyst Brooks O'Neil believes Tandem Diabetes' (TNDM) partnership with Abbott (ABT) offers the company "substantial opportunity." Abbott's Libre opens a "huge incremental opportunity" for Tandem both in the U.S. and around the world, O'Neil tells investors in a research note. In addition, the deal likely opens the "door wide" for further positive reimbursement decisions for Tandem, contends the analyst. He keeps a Buy rating on Tandem Diabetes with a $100 price target.
10/17/19
GUGG
10/17/19
INITIATION
Target $76
GUGG
Buy
Tandem Diabetes initiated with a Buy at Guggenheim
Guggenheim analyst Chris Pasquale initiated coverage of Tandem Diabetes with a Buy rating and $76 price target.
10/17/19
GUGG
10/17/19
INITIATION
Target $76
GUGG
Buy
Guggenheim starts 'remarkable' turnaround story Tandem Diabetes with Buy
Guggenheim analyst Chris Pasquale initiated coverage of Tandem Diabetes with a Buy rating and $76 price target. The analyst views the company as a "remarkable MedTech turnaround story." Management has successfully guided the company from a going concern risk at the start of 2018 to an over $4B market cap a year later, Pasquale tells investors in a research note. He sees the 19% pullback in the shares since March as creating an attractive entry point. The stock's current valuation is more than supported by Tandem's long-term growth outlook, and the upcoming Control-IQ launch representing an important near-term catalyst, says the analyst.
MDR McDermott
$1.72

0.06 (3.61%)

09/11/19
SBSH
09/11/19
NO CHANGE
Target $7
SBSH
Neutral
McDermott price target lowered to $7 from $11 at Citi
Citi analyst Andrew Kaplowitz lowered his price target for McDermott to $7 from $11 while keeping a Neutral rating on the shares. While the analyst sees "some light at the end of the tunnel" for the company on its two "troublesome" liquefied natural gas projects and believes the negative estimate revisions for CBI Legacy work may be behind the company, he says he can't rule out "further project-related noise." Further, McDermott's balance sheet is still relatively levered and some uncertainty regarding the timing of asset sales remains, Kaplowitz tells investors in a research note.
09/19/19
SBSH
09/19/19
NO CHANGE
Target $7
SBSH
Neutral
Citi sees working capital unwind as 'legitimate risk' for McDermott
Shares of McDermott dropped 63% yesterday following news that the company hired turnaround firm AlixPartners for "strategic and operational advice." Low liquidity, high leverage, and lingering headwinds associated with legacy CB&I-related projects pose elevated risk for the company, Citi analyst Andrew Kaplowitz tells investors in a research note. The analyst admits that he does not know what's causing McDermott to turn to AlixPartners. He sees a "wide range of possibilities with little visibility to near-term outcomes," which leads to his continued Neutral rating on the shares. McDermott has a "considerable amount of good assets" that are saleable and customers have an incentive to see the company succeed, says Kaplowitz. However, a working capital unwind is now a "legitimate risk" and it may be harder for McDermott to win work at this point, adds the analyst.
09/20/19
FBCO
09/20/19
NO CHANGE
Target $7
FBCO
Neutral
McDermott's plans to sell Lummus 'a last resort,' says Credit Suisse
Credit Suisse analyst Jamie Cook says McDermott's announcement that it will explore selling its Lummus technology business was considered "a last resort," but was "unfortunately needed" to improve the balance sheet. Cook, who maintains a Neutral rating and $7.00 price target, says she believes McDermott would prefer to retain some ownership in order to retain rights to be the first bidder on the EPC business if possible. She feels a transaction could occur "quickly," given the asset was already on the market recently and says she believes the stock should rally on this news given the dramatic sell off this week and that management is not considering chapter 11.
DIOD Diodes
$48.95

0.8 (1.66%)

04/17/19
LBOW
04/17/19
DOWNGRADE
LBOW
Neutral
Diodes downgraded to Neutral from Buy at Longbow
04/17/19
LBOW
04/17/19
DOWNGRADE
LBOW
Neutral
Longbow downgrades Texas Instruments, three other semis to Neutral
Longbow analyst Shawn Harrison downgraded Diodes (DIOD), ON Semiconductor (ON), Littelfuse (LFUS) and Texas Instruments (TXN) to Neutral from Buy to reflect a more conservative view of Q2 and second half sales growth relative to consensus expectations. Recent channel checks provided a more cautious view into any recovery given uncertainty in bookings in China and Europe, greater excess inventory than previously realized, and a return of semi pricing pressure, Harrison tells investors in a research note. Valuations also play a role in his downgrades of Littelfuse, Texas Instruments. For Diodes and ON Semiconductor, Harrison believes the slower demand recovery and a return of price declines will "mute clear secular tailwinds and weigh on sentiment, limiting upside."
08/19/19
WELS
08/19/19
INITIATION
Target $55
WELS
Outperform
Diodes initiated with an Outperform at Wells Fargo
Wells Fargo analyst Gary Mobley started coverage of Diodes with an Outperform rating and a $55 price target. The analyst does not believe the market fully appreciates how semiconductor industry consolidation has created a secular tailwind for the company, and does not think the accretion to be generated from the pending Lite-On Semiconductor acquisition is fully discounted in the current share price.
10/29/19
BARD
10/29/19
NO CHANGE
Target $46
BARD
Neutral
Diodes elevated to Fresh Pick designation at Baird
Baird analyst Tristan Gerra elevated Diodes to Fresh Pick after the company announced Life-On shareholders approved its proposed acquisition. He views the acquisition as strategic and positive over the medium-term and should be significantly accretive. The analyst sees multiple synergies including ramping HFAB utilization rates, cross selling opportunities, and a refocusing on high margin customers and end-markets. Gerra maintained his Neutral rating and raised his price target to $46 from $42 on Diodes shares.
AAN Aaron's
$74.00

0.005 (0.01%)

09/26/19
BOFA
09/26/19
INITIATION
Target $75
BOFA
Buy
Aaron's initiated with a Buy at BofA/Merrill
BofA/Merrill analyst Jason Haas initiated Aaron's (AAN) with a Buy rating and a price target of $75. The analyst expects the company to produce "significant upside" to revenue and EPS from the large national retailer partnerships in its Progressive Leasing segment, adding that its rent-to-own contracts through Best Buy (BBY), Lowe's (LOW), Wayfair (W) and Overstock (OSTK) could more than double the company's sales and earnings over time.
09/26/19
09/26/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Dropbox (DBX) assumed with an Outperform at RBC Capital. 2. Rigel Pharmaceuticals (RIGL) assumed with an Overweight at JPMorgan. 3. Aaron's (AAN) initiated with a Buy at BofA/Merrill. 4. Cooper-Standard (CPS) resumed with a Buy at Roth Capital. 5. Carvana (CVNA) initiated with a Neutral at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/16/19
RAJA
10/16/19
NO CHANGE
Target $80
RAJA
Strong Buy
Aaron's price target raised to $80 from $72 at Raymond James
Raymond James analyst Budd Bugatch raised his price target for Aaron's (AAN) to $80 from $72 and reiterated a Strong Buy rating following the recent news that Lowe's (LOW) had rolled out the Aaron's/Progressive virtual lease-to-own program nationwide. Bugatch tells investors in a research note that he believes this will be a terrific "win" for Progressive and create much value for Aaron's and says he can envision ~$30 in permanent incremental share value.
10/21/19
LOOP
10/21/19
NO CHANGE
Target $90
LOOP
Buy
Aaron's price target raised to $90 from $73 at Loop Capital
Loop Capital analyst Anthony Chukumba raised his price target on Aaron's (AAN) to $90 and kept his Buy rating ahead of its Q3 results on November 4th, reflecting the company's recent announcement of rolled out Progressive offering at Lowe's (LOW) nationwide. The analyst expects investors to focus on the management's earnings call commentary regarding Progressive sales and the "invoice volume per active door" growth metric, along with any updates on its partnership with Best Buy (BBY). Chukumba is also raising his FY20 EPS view on Aaron's to $4.97 from $4.54.
GRPN Groupon
$3.01

0.14 (4.88%)

02/04/19
GSCO
02/04/19
INITIATION
Target $3.5
GSCO
Neutral
Groupon initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Michael Ng started Groupon with a Neutral rating and $3.50 price target. While the company's business model is in transition, its domestic customer base is declining and should continue to do so, particularly as Groupon moderates its domestic marketing spending, Ng tells investors in a research note. However, he believes these "challenges are well understood" at current share levels.
02/04/19
02/04/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Yelp (YELP) initiated with a Buy at Goldman Sachs while Groupon (GRPN) was initiated with a Neutral, and Match Group (MTCH) and Shutterfly (SFLY) were initiated with a Sell. 2. eHealth (EHTH) initiated with an Outperform at Evercore ISI. 3. Okta (OKTA) initiated with an Equal Weight at Morgan Stanley. 4. Lonestar Resources (LONE) initiated with an Outperform at Cowen. 5. Kopin (KOPN) initiated with a Buy at Ladenburg. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/03/19
RHCO
11/03/19
NO CHANGE
Target $37
RHCO
Hold
SunTrust sees chance of change high ahead of Yelp Q3 report
SunTrust analyst Matthew Thornton maintained a Hold rating and $37 price target on Yelp (YELP) shares. He noted that the company reports Q3 earnings on November 7 after the market close, and believes the consensus revenue number will be a "high hurdle." More importantly, according to the analyst, the company has three new board members, is in the middle of a CFO transition, has what the analyst sees as "overly aggressive" long-term guidance, and there is reported takeover interest from Groupon (GRPN). This leads Thornton to believe "the prospect of change is higher than it's been." He does not think that more buybacks will be enough, he thinks acquisitions will be scrutinized, and he added that the company has already tried to "tinker with the business model" recently. So, he concluded that "real change (to change the investment narrative) may require significant partnership(s), leadership change, and/or a sale," and he believes the numbers work for a Groupon-Yelp deal.
MOS Mosaic
$21.36

0.72 (3.49%)

09/20/19
CLVD
09/20/19
NO CHANGE
CLVD
Neutral
Mosaic estimates lowered on weaker pricing at Cleveland Research
To reflect the impact of weaker phosphate and potash pricing and profitability, Cleveland Research analyst Mike Piken lowered his 2019 earnings per share estimate for Mosaic to 96c from $1.22, which sits 23c below the consensus. The analyst is surprised that Mosaic didn't lower its fiscal 2018 guidance at a recent conference where it announced its phosphate production cut. Piken, who still sees "plenty of growth opportunities" for Mosaic, keeps a Neutral rating on the shares.
09/23/19
CEDG
09/23/19
INITIATION
Target $22
CEDG
Equal Weight
Mosaic initiated with an Equal Weight at Consumer Edge
Consumer Edge initiated Mosaic with an Equal Weight and $22 price target.
09/27/19
RBCM
09/27/19
NO CHANGE
Target $26
RBCM
Outperform
Mosaic price target lowered to $26 from $32 at RBC Capital
RBC Capital analyst Andrew Wong lowered his price target on Mosaic to $26, saying he is reducing his expectations of a phosphate recovery due to uncertainty around China and India. The analyst is keeping his Outperform rating on the shares however, noting that the valuation on Mosaic is still "reasonable", even as he sees a "challenging" operating environment for the company over the next 3-6 months.
10/25/19
CLVD
10/25/19
NO CHANGE
CLVD
CF Industries, Mosaic estimates lowered at Cleveland Research
Cleveland Research analyst Mike Piken lowered his FY19 estimates for both CF Industries (CF) and Mosaic (MOS) to reflect the fact that phosphate market conditions have continued deteriorating and he sees increased odds of an average to worse fall fertilizer application season in the U.S. Piken has Neutral ratings on both stocks.
UBER Uber
$31.09

-0.23 (-0.73%)

10/25/19
10/25/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Essa Pharma (EPIX) initiated with an Outperform at Oppenheimer. 2. Uber (UBER) initiated with a Buy at Guggenheim. 3. LogMeln (LOGM) assumed with a Sector Perform at RBC Capital. 4. MannKind (MNKD) initiated with an Overweight at Cantor Fitzgerald. 5. Sanderson Farms (SAFM) initiated with an Underperform at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/25/19
NRCS
10/25/19
NO CHANGE
NRCS
Neutral
Northcoast checks show 'healthy' ride-hailing conditions during Q3
Northcoast analyst John Healy says his Q3 channel checks into ride-hailing conditions in the U.S. market indicate a backdrop that was "healthy at the margin with no meaningful slowdown." Further, Uber Technologies (UBER) seemed to win some of the "tug-of-war battle" between itself and Lyft (LYFT), as drivers seemed "marginally more pleased" with their time spent with Uber, Healy tells investors in a research note. He believes that at the margin, drivers during Q3 moved a bit more of their usage towards Uber. Meanwhile, Lyft continues to "inch pricing higher" for rides in many markets, while Uber is taking a more wait and see approach, says Healy. The analyst raised his Q3 earnings per share estimate for Lyft to (61c) from (72c), and lowered his Q3 estimate for Uber to (65c) from (63c). Healy keeps a Neutral rating on both stocks, but sees Lyft as the "cleaner/pure play story and at the margin more attractive."
10/28/19
DBAB
10/28/19
NO CHANGE
Target $29
DBAB
Hold
Uber launch could drive adoption of Green Dot powered card, says Deutsche Bank
Deutsche Bank analyst Ashish Sabadra said the launch of Uber Money (UBER) could drive greater adoption of the Uber debit card, which is powered by Green Dot (GDOT). Since there are no monthly fees for the debit card account, Sabadra thinks the primary monetization will be through interchange and other fees. The analyst keeps a Hold rating on Green Dot shares with a $29 price target.
10/31/19
GSCO
10/31/19
UPGRADE
Target $58
GSCO
Buy
Lyft upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Heath Terry upgraded Lyft (LYFT) to Buy from Neutral with a price target of $58, down from $71. The stock in premarket trading is up 4%, or $1.92, to $46.03. The company reported better than expected Q3 revenue and management noted a trend toward higher prices across the industry, incremental engagement per rider, and a less promotional competitive environment, Terry tells investors in a research note. Lyft continues to gain share and is beginning to show the operational efficiencies, says the analyst, who believes the stock's risk/reward is favorable at current levels. Lyft competitor Uber Technologies (UBER) is trading up 15c to $33.90.
MAXR Maxar Technologies
$9.94

0.985 (11.00%)

03/01/19
TDSI
03/01/19
DOWNGRADE
TDSI
Hold
Maxar Technologies downgraded to Hold from Speculative Buy at TD Securities
03/01/19
03/01/19
DOWNGRADE
Target $9

Hold
Maxar Technologies downgraded to Hold at TD Securities after disappointing Q4
As previously reported, TD Securities analyst Tim James downgraded Maxar Technologies to Hold from Speculative Buy and lowered his price target to $9 from $18.50 after its below-consensus Q4 results. The analyst says his previous constructive thesis attributing the company's weakness to the divestable GEO comsat business was incorrect as the company indicated it will continue to operate it at a loss. James added that the EBITDA of Maxar's Services and Imagery segment was also soft and recommends that investors await for evidence of improvement before considering buying shares again.
03/01/19
03/01/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. L Brands (LB) downgraded to Market Perform from Outperform at Bernstein with analyst Jamie Merriman saying her Outperform rating was based on a view that investors were paying for Bath & Body Works with a free option on Victoria's Secret. 2. American Airlines (AAL) and Delta Air Lines (DAL) downgraded to Hold from Buy at Deutsche Bank. 3. Devon Energy (DVN) downgraded to Sector Perform from Outperform at RBC Capital. 4. O'Reilly Automotive (ORLY) downgraded to Neutral from Overweight at Atlantic Equities with analyst Sam Hudson citing valuation and raised his price target to $400 from $370. 5. Maxar Technologies (MAXR) downgraded to Hold from Speculative Buy at TD Securities and to Underperformer from Neutral at CIBC. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/10/19
JPMS
09/10/19
INITIATION
Target $12
JPMS
Overweight
Maxar Technologies initiated with an Overweight at JPMorgan
JPMorgan analyst Benjamin Arnstein started Maxar Technologies with an Overweight rating and $12 price target. The analyst views Maxar as a "high-risk/high-reward opportunity" in the Space industry. The next 24 months are critical as the company progresses on its turnaround plan and addresses its high leverage and debt levels, which should create value for equity holders, Arnstein tells investors in a research note. He believes Maxar should generate cash in 2021.
PI Impinj
$33.45

-1.09 (-3.16%)

07/30/19
PIPR
07/30/19
NO CHANGE
Target $40
PIPR
Overweight
Impinj price target raised to $40 from $32 at Piper Jaffray
Piper Jaffray analyst Troy Jensen raised his price target for Impinj to $40 from $32 saying the company reported "strong" June quarter results. The analyst believes the RFID market has entered a new phase of growth with broad based strength across multiple verticals. And while Impinj's September quarter guidance was slightly below plan, management has exceeded the high-end of guidance for the past five quarters, Jensen tells investors in a research note. He believes the company is being conservative and reiterates an Overweight rating on the shares.
07/30/19
ADAM
07/30/19
NO CHANGE
Target $39
ADAM
Buy
Impinj price target raised to $39 from $35 at Canaccord
Canaccord analyst T. Michael Walkley raised his price target on Impinj to $39 from $35 following strong Q2 results. The analyst anticipates strong long-term growth trends driven by new industry broader adoption after it cleared hundreds of millions of endpoint inventory. Walkley reiterated his Buy rating on Impinj shares.
07/30/19
ROTH
07/30/19
NO CHANGE
Target $38
ROTH
Buy
Impinj price target raised to $38 from $31 at Roth Capital
Roth Capital analyst Scott Searle raised his price target for Impinj to $38 from $31 after the company reported "strong" Q2 results with a generally in-line guide. The analyst reiterates a Buy rating on the shares.
08/16/19
ADAM
08/16/19
NO CHANGE
Target $42
ADAM
Buy
Impinj price target raised to $42 from $39 at Canaccord
Canaccord analyst T. Michael Walkley raised his price target on Impinj to $42 from $39 following meetings with management. The analyst said management highlighted the growing uses of RAI RFID across numerous vertical markets, including new industry opportunities with strong long-term growth potential. He anticipates double-digit revenue growth through 2021 with growing RAIN opportunities. Walkley reiterated his Buy rating on Impinj shares.
ENDP Endo
$4.86

0.05 (1.04%)

07/15/19
MSCO
07/15/19
DOWNGRADE
Target $3
MSCO
Underweight
Endo downgraded to Underweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst David Risinger downgraded Endo International to Underweight from Equal Weight and cut his price target for the shares to $3 from $8.
07/15/19
MSCO
07/15/19
DOWNGRADE
MSCO
Underweight
Endo, Teva downgraded to Underweight on underappreciated risks at Morgan Stanley
As previously reported, Morgan Stanley analyst David Risinger downgraded Endo International (ENDP) and Teva Pharmaceutical (TEVA), both to Underweight from Equal Weight, cut his price target on Endo shares to $3 from $8 and lowered his price target for Teva shares to $6 from $16. In the wake of Amneal's (AMRX) recent 28% EBITDA guidance cut, Risinger noted that Amneal faces company-specific challenges but also said he is concern about potentially worsening U.S. competitive pricing pressure. He is worried that Endo and Teva both face "underappreciated" risks from buying group pressure being worse than expected, increasing competition among generic manufacturers and the fact that opioid litigation is "just getting started" with thousands of lawsuits having been filed. Risinger also cut his earnings estimates for Mylan (MYL) lowered his price target on its shares to $22 from $32, though he maintains an Overweight rating on that generic drugmaker, citing low valuation and the potential for corporate action. Risinger additionally lowered his price target on Amneal shares to $4 from $12.
07/15/19
07/15/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Teva (TEVA) and Endo (ENDP) downgraded to Underweight from Equal Weight at Morgan Stanley. 2. Marriott (MAR) downgraded to Neutral from Buy at Longbow with analyst Alton Stump citing valuation. 3. General Electric (GE) downgraded to Neutral from Buy at UBS with analyst Damian Karas saying that a "notable" decline in interest rates and the continued weakness in the power market combine toward a "more balanced" upside with downside. 4. WageWorks (WAGE) downgraded to Hold from Buy at Stifel with analyst David Grossman saying he does not envision a competing takeover offer for the company. 5. L Brands (LB) downgraded to Neutral from Buy at Citi with analyst Paul Lejuez saying his former view on the stock was based on the belief that a Victoria's Secret turnaround could be successful if the brand adopted a more inclusive approach. However, with management slow to implement meaningful change, and "cultural norms shifting away from them," it may be "too little too late" for a meaningful turnaround at Victoria's Secret. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/11/19
GUGG
09/11/19
INITIATION
GUGG
Neutral
Endo assumed with a Neutral at Guggenheim
Guggenheim analyst Dana Flanders assumed coverage of Endo International with a Neutral rating and a $2-$4 fair value range. The analyst noted that the upcoming opioid litigation, which Endo has significant exposure to, will be hard to call, but he estimates $3B-$4B in opioid liability paid out over ten years, and believes the risks are already reflected in the stock.
PKOH Park-Ohio
$32.54

0.69 (2.17%)

GAIN Gladstone Investment
$12.95

0.02 (0.15%)

05/15/19
LTCO
05/15/19
DOWNGRADE
LTCO
Neutral
Gladstone Investment downgraded to Neutral from Buy at Ladenburg
05/15/19
05/15/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Kirkland's (KIRK) downgraded to Neutral from Buy at B. Riley FBR with analyst Jeffrey Van Sinderen saying he sees a "confluence" of headwinds hurting the company's recovery in 2019. 2. Buckeye Partners (BPL) downgraded to Sell from Hold at Argus and to Neutral from Buy at UBS. 3. ElectroCore (ECOR) downgraded to Neutral from Buy at BTIG with analyst Sean Lavin saying payor wins are not yet converting to sales. 4. Zayo Group (ZAYO) downgraded to Market Perform from Outperform at Cowen. 5. Gladstone Investment (GAIN) downgraded to Neutral from Buy at Ladenburg. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CPTA Capitala Finance
$8.27

0.025 (0.30%)

08/06/19
LTCO
08/06/19
DOWNGRADE
LTCO
Neutral
Capitala Finance downgraded to Neutral from Buy at Ladenburg
08/06/19
08/06/19
DOWNGRADE

Neutral
Capitala Finance downgraded to Neutral after quarterly results at Ladenburg
As previously reported, Ladenburg analyst Christopher Nolan downgraded Capitala Finance to Neutral from Buy following quarterly results. The analyst notes that the company reported in line Q2 EPS, but NAV/share decreased 18% quarter over quarter driven primarily by a $20M realized loss from its exit from AAE Acquisition, and also impacted by unrealized depreciation.
10/20/19
KBWI
10/20/19
DOWNGRADE
Target $7.5
KBWI
Underperform
Capitala downgraded to Underperform from Market Perform at Keefe Bruyette
Keefe Bruyette analyst Ryan Lynch downgraded Capitala Finance to Underperform from Market Perform with an unchanged price target of $7.50. The stock's valuation is too high given Capitala's track record of below-average and negative historical economic returns, Lynch tells investors in a research note. The company has had "major" credit issues over the past several years, says the analyst, who adds that Capitala's valuation is at a "significant" premium to peers.
HLIO Helios Technologies
$42.18

0.69 (1.66%)

MAR Marriott
$130.19

2.04 (1.59%)

09/11/19
09/11/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Hilton (HLT) initiated with an Outperform at Bernstein while Marriott (MAR) initiated with a Market Perform. 2. Ceridian (CDAY) initiated with an Overweight at Cantor Fitzgerald. 3. PacifiCare (PHS) initiated with an Outperform at William Blair. 4. Ollie's Bargain Outlet (OLLI) initiated with a Buy at Craig-Hallum. 5. ADP (ADP) initiated with an Outperform at Cowen while Paychex (PAYX) initiated with a Market Perform. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/16/19
RBCM
09/16/19
NO CHANGE
Target $148
RBCM
Outperform
Marriott price target raised to $148 from $146 at RBC Capital
RBC Capital analyst Wes Golladay kept his Outperform rating on Marriott and nudged his price target higher to $148 from $146 after talks with its CFO Leeny Oberg. The analyst notes that the discussions highlighted the strength of the company's Bonvoy loyalty program as well as its "elevated" unit growth and positive RevPAR trends, saying international tourism is particularly strong in U.K. and Japan markets. Golladay also points to the company's positioning in the Asia Pacific, where hotel owners continue to have "high interest" for developing Marriott-branded hotels.
09/19/19
GSCO
09/19/19
DOWNGRADE
Target $37
GSCO
Neutral
Hilton Grand Vacations downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Stephen Grambling downgraded Hilton Grand Vacations (HGV) to Neutral from Buy while raising his price target for the shares to $37 from $35. While leveraged buyout internal rate of returns could be attractive to $40 per share or higher, other names in the Lodging space offer better risk-adjusted returns, Grambling tells investors in a research note. The analyst's estimates remain below management's long-term earnings target and consensus in fiscal 2021 as he anticipates a slower sell-through of owned inventory. The delayed sell-through is likely to also postpone any free cash flow inflection and raise Hilton Grand Vacations' earnings risk in the near term in the event of any macro deterioration, contends Grambling. The analyst this morning also upgraded Hyatt Hotels (H) to Buy from Neutral and reiterated Buy ratings on Marriott (MAR), Hilton (HLT) and Wyndham Hotels & Resorts (WH). Marriott is on his firm's Conviction List.
10/16/19
BMOC
10/16/19
INITIATION
Target $128
BMOC
Market Perform
Marriott initiated with a Market Perform at BMO Capital
BMO Capital analyst Ari Klein initiated coverage of Marriott with a Market Perform rating and $128 price target. The analyst says the company's scale with over 1.3M rooms in its global portfolio is impressive and its "asset-light approach" yields a high margin and drives strong free cash flows. However, Klein is concerned with the elevated macro headwinds that are likely to pressure Marriott's RevPAR and also weigh on its incentive fees, which he sees as more susceptible to industry cyclicality while representing about 17% of the company's gross fee revenues.
PRU Prudential
$94.63

1.66 (1.79%)

09/12/19
GSCO
09/12/19
UPGRADE
Target $68
GSCO
Conviction Buy
Voya Financial upgraded to Conviction Buy from Buy at Goldman Sachs
Goldman Sachs analyst Alex Scott added Voya Financial (VOYA) to his firm's Americas Conviction List while maintaining a Buy rating on the shares. He also raised his price target for the shares to $68 from $59. Voya has a better ability to beat earnings estimates in the near term as well as in 2020 and 2021 relative to Prudential Financial (PRU), Scott tells investors in a research note. He believes expense reduction, share count reduction, and the addition of a large record keeping contract earn in can drive the upside for Voya.
09/12/19
GSCO
09/12/19
DOWNGRADE
Target $99
GSCO
Buy
Prudential downgraded to Buy from Conviction Buy at Goldman Sachs
Goldman Sachs analyst Alex Scott removed Prudential Financial (PRU) from his firm's Americas Conviction List while maintaining a Buy rating on the shares. The analyst also lowered his price target for the stock to $99 from $107. Voya Financial (VOYA) has a better ability to beat earnings estimates in the near term as well as in 2020 and 2021 relative to Prudential, Scott tells investors in a research note. While a good amount "near-term negativity" is already priced into Prudential, the shares do not have many catalysts in the next six months outside of earnings beats, adds the analyst. He sees a more challenging near-term setup for Prudential and shifts his conviction to Voya.
09/12/19
09/12/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Square (SQ) assumed with a Hold from Buy at Canaccord with analyst Joseph Vafi saying the stock will continue to react to changes in payment volume growth, which has been showing steady deceleration. 2. Deere (DE) and Caterpillar (CAT) were downgraded to Market Perform from Outperform at Wells Fargo. 3. Prudential (PRU) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Alex Scott saying Voya Financial (VOYA) has a better ability to beat earnings estimates in the near term as well as in 2020 and 2021 relative to Prudential. 4. Invesco (IVZ) downgraded to Neutral from Overweight at JPMorgan with analyst Kenneth Worthington saying continued Oppenheimer outflows "show few signs of slowing," making it unlikely for the stock to outperform despite a cheap valuation. 5. DXC Technology (DXC) was downgraded to In Line from Outperform at Evercore ISI and to Neutral from Positive at Susquehanna. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/14/19
SBSH
10/14/19
NO CHANGE
SBSH
Sell
Citi opens 'Negative Catalyst Watches' on Brighthouse, Prudential
Citi analyst Suneet Kamath opened "Negative Catalyst Watches" on both Sell-rated Brighthouse Financial (BHF) and Neutral-rated Prudential Financial (PRU) into Q3 earnings season. For Brighthouse, the analyst has concerns over low interest rates and distributable earnings. For Prudential, he sees the potential for an earnings disappointment. For the life insurance sector, 2020 consensus estimates could be too high due to pressure from low rates and the potential for an ongoing negative impact from Q3 assumption reviews. Further, forward estimates for U.S. life do not reflect the potential for higher credit losses, which are excluded from operating earnings, Kamath tells investors in a research note.
HTZ Hertz
$14.13

0.4 (2.91%)

03/04/19
03/04/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Foot Locker (FL) upgraded to Buy from Hold at Pivotal Research with analyst Mitch Kummetz saying the company on Friday reported much better than expected Q4 results, and its fiscal 2019 same-store-sales and earnings growth outlook was also well above consensus. 2. Hasbro (HAS) upgraded to Market Perform from Underperform at BMO Capital with analyst Gerrick Johnson saying the stock's multiple will expand as "major theatrical events" approach later in the year. 3. Hertz (HTZ) upgraded to Buy from Neutral at Northcoast. 4. Extended Stay America (STAY) upgraded to Buy from Neutral at Goldman Sachs with analyst Stephen Grambling citing the company's Q4 earnings report. 5. Kraft Heinz (KHC) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Dara Mohsenian saying he believes FY19 estimates now look achievable following their recent correction. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/11/19
BARD
07/11/19
NO CHANGE
Target $17
BARD
Outperform
Verra's Outperform rating backed following Hertz announcement, says Baird
Baird analyst David Koning reiterated an Outperform rating and $17 price target on Verra Mobility (VRRA) following the announcement that Hertz (HTZ) customers, as well as customers of the company's Dollar and Thrifty, can now rent a car using a debit card across European countries. In a research note to investors, Koning notes that the countries where debit is now accepted include Belgium, Czech Republic, France, Germany, Italy and the U.K. which, based on World Bank data, represent about 70% of the EU population. The analyst notes that one of the keys to Verra's tolling business is that customers must have a credit or debit card on file to pay for the tolls.
08/08/19
LEHM
08/08/19
UPGRADE
Target $19
LEHM
Overweight
Hertz upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Brian Johnson upgraded Hertz Global Holdings to Overweight from Equal Weight with an unchanged price target of $19. The company's "impressive" Q2 plus favorable industry dynamics offers a "better runway for transformation," Johnson tells investors in a research note. The analyst views Hertz as a turnaround story "incrementally validated" by recent events, and he believes the recent share weakness presents a buying opportunity.
08/08/19
08/08/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Disney (DIS) upgraded to Outperform from Neutral at Credit Suisse with analyst Douglas Mitchelson saying he sees less risk to estimates now that the fiscal 2020 consensus earnings per share estimate dropped from over $8 per share a year ago to ~$6 per share today. 2. Lyft (LYFT) upgraded to Outperform from Neutral at Wedbush and to Neutral from Underweight at Atlantic Equities. 3. Roku (ROKU) was upgraded to Overweight from Equal Weight at Stephens and to Buy from Neutral at Rosenblatt. 4. Hertz (HTZ) upgraded to Overweight from Equal Weight at Barclays with analyst Brian Johnson saying the company's "impressive" Q2 plus favorable industry dynamics offers a "better runway for transformation." 5. Dollar General (DG) upgraded to Buy from Neutral at Goldman Sachs with analyst Christopher Prykull saying the broader market volatility that has brought shares of Dollar General down has created an opportunity for investors to step into a "favorably positioned" retailer. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

DY

Dycom

$50.93

0.495 (0.98%)

12:48
12/08/19
12/08
12:48
12/08/19
12:48
Syndicate
Dycom withdraws senior notes offering due to market conditions »

Dycom Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

IMV

IMV Inc.

$2.92

0.07 (2.46%)

12:30
12/08/19
12/08
12:30
12/08/19
12:30
Hot Stocks
IMV announces updated results from Phase 2 study of DPX-Survivac »

IMV Inc. announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KURA

Kura Oncology

$15.67

0.48 (3.16%)

12:27
12/08/19
12/08
12:27
12/08/19
12:27
Hot Stocks
Kura Oncology announces updates for lead drug candidate tipifarnib »

Kura Oncology announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

PTLA

Portola Pharmaceuticals

$29.22

0.86 (3.03%)

12:24
12/08/19
12/08
12:24
12/08/19
12:24
Hot Stocks
Portola presents interim results from Phase 2a study of cerdulatinib »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

11:25
12/08/19
12/08
11:25
12/08/19
11:25
Conference/Events
Piper Jaffray biotech analysts to hold a KOL luncheon »

Biotech Analysts hold a…

FATE

Fate Therapeutics

$13.64

0.07 (0.52%)

10:49
12/08/19
12/08
10:49
12/08/19
10:49
Hot Stocks
Fate Therapeutics announces vivo preclinical data for FT596 »

Fate Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STOK

Stoke Therapeutics

$28.91

3.99 (16.01%)

10:04
12/08/19
12/08
10:04
12/08/19
10:04
Hot Stocks
Stoke Therapeutics presents STK-001 preclinical data in Dravet syndrome »

Stoke Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUTL

Autolus Therapeutics

$14.60

-0.18 (-1.22%)

09:25
12/08/19
12/08
09:25
12/08/19
09:25
Hot Stocks
Autolus announces new data highlighting progress on AUTO3 »

Autolus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

AGIO

Agios Pharmaceuticals

$40.93

0.81 (2.02%)

09:22
12/08/19
12/08
09:22
12/08/19
09:22
Hot Stocks
Agios says proof-of-concept has been established for mitapivat »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

ZIOP

Ziopharm

$5.16

0.06 (1.18%)

09:20
12/08/19
12/08
09:20
12/08/19
09:20
Hot Stocks
Ziopharm reports pre-clinical data of Rapid Personalized Manufacture »

Ziopharm Oncology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

TGTX

TG Therapeutics

$7.11

-0.57 (-7.42%)

09:18
12/08/19
12/08
09:18
12/08/19
09:18
Hot Stocks
TG Therapeutics reports triple therapy data from Phase I/II study of ublitux »

TG Therapeutics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

KPTI

Karyopharm

$16.30

-1.15 (-6.59%)

09:16
12/08/19
12/08
09:16
12/08/19
09:16
Hot Stocks
Karyopharm says four posters will be presented at ASH »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPHA

Innate Pharma

$6.30

(0.00%)

09:13
12/08/19
12/08
09:13
12/08/19
09:13
Hot Stocks
Innate Pharma reports long-term data from Phase III trial of Lumoxiti »

Innate Pharma shared new,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REGN

Regeneron

$372.26

4.02 (1.09%)

09:11
12/08/19
12/08
09:11
12/08/19
09:11
Hot Stocks
Regeneron reports initial data for REGN5458 in myeloma patients »

Regeneron Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

09:09
12/08/19
12/08
09:09
12/08/19
09:09
Hot Stocks
Blueprint reports 77% overall response rate in 48 patients from Explorer trial »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

09:06
12/08/19
12/08
09:06
12/08/19
09:06
Hot Stocks
Blueprint announces initial data from Phase 2 Pioneer trial in mastocytosis »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

PCG

PG&E

$9.65

-0.13 (-1.33%)

08:12
12/08/19
12/08
08:12
12/08/19
08:12
Periodicals
PG&E settlement threatens bondholders plan, WSJ reports »

PG&E's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

SYRS

Syros Pharmaceuticals

$4.60

-0.02 (-0.43%)

08:08
12/08/19
12/08
08:08
12/08/19
08:08
Hot Stocks
Syros announces fetal hemoglobin repressor using gene control platform »

Syros Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

08:06
12/08/19
12/08
08:06
12/08/19
08:06
Hot Stocks
AbbVie says post-hoc analysis supports benefit of venetoclax in combination »

AbbVie presented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

08:03
12/08/19
12/08
08:03
12/08/19
08:03
Hot Stocks
Genentech reports data from two Phase III Venclexta studies in leukemia »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 16

    Dec

ORTX

Orchard Therapeutics

$11.85

0.37 (3.22%)

07:59
12/08/19
12/08
07:59
12/08/19
07:59
Hot Stocks
Orchard to present data from multiple programs at ASH meeting »

Orchard Therapeutics said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

06:55
12/08/19
12/08
06:55
12/08/19
06:55
Conference/Events
Sierra Oncology to hold an analyst and investor event »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

RUHN

Ruhnn

$6.19

-0.2 (-3.13%)

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Ruhnn management to meet with Mizuho »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Sierra Oncology to hold an analyst and investor event »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Piper Jaffray biotech analysts to hold a KOL luncheon »

Biotech Analysts hold a…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.